Livanova Announces Core-Vns 24-Month Data Show Adjunctive Vns Therapy Is Associated With Substantial Reductions In Generalized Tonic-Clonic Seizures In People With Drug-Resistant Epilepsy
June 5 (Reuters) - LivaNova PLC LIVN.O:
LIVANOVA ANNOUNCES CORE-VNS 24-MONTH DATA SHOW ADJUNCTIVE VNS THERAPY IS ASSOCIATED WITH SUBSTANTIAL REDUCTIONS IN GENERALIZED TONIC-CLONIC SEIZURES IN PEOPLE WITH DRUG-RESISTANT EPILEPSY
LIVANOVA PLC - 77% MEDIAN SEIZURE REDUCTION, 43% SEIZURE FREEDOM AT 24 MONTHS
LIVANOVA PLC - 52% MEDIAN SEIZURE REDUCTION AT THREE MONTHS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
TSLA Q1 Earnings Preview: Tesla Snaps 8-Week Slump—Now Buy the Dip or Wait?

AI Chip Startup Cerebras Refiles for IPO, Testing Nvidia’s Pricing Power

Intel Q1 Earnings Preview: Triple Test of CPU, 18A Yields and Foundry Orders

Allbirds Ditches Sneakers and Pivots to AI Computing - Is BIRD Stock Still Worth Buying After a 600% Surge?

Bitcoin Breaks $78,000 Amid U.S.-Iran Conflict, Can It Return to $100,000 in 2026?

Tradingkey







